Myriad Genetics price target lowered to $14 from $24 at Piper Sandler
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...
bovnews1d
The Myriad Genetics Inc Enigma: What’s Causing the Wild Swings in MYGN Stock?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.75% of ...
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...
Myriad Genetics: Navigating Through A Setback
Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...
Myriad Genetics stock hits 52-week low at $12.16 amid market challenges
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has ...
Nasdaq7d
Myriad Genetics Launches "Know More Sooner" Educational Website for Prenatal Genetic Testing
Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...
Forbes5d
Myriad Genetics
Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through ...
Yahoo Finance24d
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate ...
Hosted on MSN1y
Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing
Myriad Genetics, Inc. MYGN and Intermountain Precision Genomics, a service of Intermountain Health, recently secured the New York State Clinical Laboratory Permit to offer solid tumor testing to ...
Nasdaq20d
Myriad Genetics Partners with Hannah Storm to Promote Breast Cancer Risk Awareness Through Genetic Testing
Myriad Genetics partners with broadcaster Hannah Storm to promote breast cancer risk assessment and the importance of family health history. Myriad Genetics, Inc. has announced a collaboration ...
The Bakersfield Californian1d
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...